Trusted Resources: News & Meetings
Latest announcements and gatherings
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis Reduction
Top-line results from the OPTIC trial showed that the phase 3 study met its primary endpoint, demonstrating that more patients with active thyroid eye disease assigned teprotumumab experienced a meaningful improvement in proptosis, or protrusion of the eyeball, compared with patients assigned placebo, according to a press release from Horizon Pharma.
In the study, designed to investigate the efficacy, tolerability and safety of teprotumumab in patients with active thyroid eye disease, researchers assigned 83 patients to teprotumumab or placebo in eight IV infusions (10 mg/kg for the first infusion followed by 20 mg/kg for the remaining seven infusions) every 3 weeks for 21 weeks, according to the release. The primary endpoint was a 2 mm or more reduction of proptosis in the study eye, without deterioration in the fellow eye, at week 24. Proptosis is the main cause of morbidity in thyroid eye disease.
myBinderRelated Content
-
Debate Over Universal Screening for Thyroid Dysfunction in Pregnancy Centers on What to TreatThe question about screening for thyroid...
-
The University of Kansas Medical CenterThe Head and Neck Surgery Team in the De...
-
Diagnosis and Management of Graves Disease – David Cooper, MDEdward H. Livingston, MD discusses Grave...
-
Reversible Pulmonary Hypertension and Clinical Right Heart Failure Associated With Graves’ DiseaseBackground: Heart failure is typically ...
-
Latin American Thyroid Society CongressThe XIX Latin American Thyroid Society C...
-
2018 European Thyroid Association Guideline for the Management of Graves’ HyperthyroidismGraves' disease (GD) is a systemic autoi...
-
Stress Triggers the Onset and the Recurrences of Hyperthyroidism in Patients With Graves’ DiseaseThe aim of this study was to evaluate th...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google